Cargando…
Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
New chimeric inhibitors targeting the epidermal growth factor (EGFR) and histone deacetylases (HDACs) were synthesized and tested for antineoplastic efficiency in solid cancer (prostate and hepatocellular carcinoma) and leukemia/lymphoma cell models. The most promising compounds, 3BrQuin-SAHA and 3C...
Autores principales: | Goehringer, Nils, Biersack, Bernhard, Peng, Yayi, Schobert, Rainer, Herling, Marco, Ma, Andi, Nitzsche, Bianca, Höpfner, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395095/ https://www.ncbi.nlm.nih.gov/pubmed/34445133 http://dx.doi.org/10.3390/ijms22168432 |
Ejemplares similares
-
Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021) -
Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Ma, Andi, et al.
Publicado: (2022) -
Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
por: Bär, Sofia Isolde, et al.
Publicado: (2022) -
HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022) -
Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023)